19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy

Magnetic Resonance in Medicine

Volumn 59, Issue 1, 2008, Pages 19-27

  Cron, Greg O ^a,b   Beghein, Nelson ^a   Ansiaux, Réginald ^a   Martinive, Philippe ^a   Feron, Olivier ^a   Gallez, Bernard ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CMFA/REMA   (Belgium)

Author keywords

Botox; BQ123; Cancer; Fluorine NMR; Thalidomide

Indexed keywords

CHEMOTHERAPY; DISEASES; TUMORS;

BOTOX; BOTULINUM NEUROTOXIN TYPE A; BQ123; CANCER; IN-VIVO SPECTROSCOPY; STUDENT T TESTS; THALIDOMIDE; TUMOR GROWTH;

NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

BOTULINUM TOXIN A; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); GEMCITABINE; THALIDOMIDE; ANTINEOPLASTIC ANTIMETABOLITE; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG UPTAKE; FLUORINATION; FLUORINE NUCLEAR MAGNETIC RESONANCE; GROWTH INHIBITION; KINETICS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; STUDENT T TEST; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BOTULINUM TOXIN TYPE A; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DRUG SYNERGISM; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; THALIDOMIDE;

EID: 37549032118     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21469     Document Type: Article

References (38)

1. van Laarhoven HW, Punt CJ, Kamm YJ, Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy. Crit Rev Oncol Hematol 2005;56:321-343.
2. Yu JX, Kodibagkar VD, Cui W, Mason RP. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem 2005;12:819-848.
3. Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr Drug Metab 2000;1:271-303.
4. Robinson SP, Barton SJ, McSheehy PM, Griffiths JR. Nuclear magnetic resonance spectroscopy of cancer. Br J Radiol 1997;70:60-69.
5. van Laarhoven HW, Klomp DW, Kamm YJ, Punt CJ, Heerschap A. In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res 2003;63:7609-7612.
6. Dzik-Jurasz AS, Collins DJ, Leach MO, Rowland IJ. Gallbladder localization of (19)F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil. Magn Reson Med 2000;44:516-520.
7. Wolf W, Presant CA, Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 2000;41:55-74.
8. van Laarhoven HW, Gambarota G, Lok J, Lammens M, Kamm YL, Wagener T, Punt CJ, van der Kogel AJ, Heerschap A. Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. Neoplasia 2006;8:477-487.
9. McSheehy PM, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der Borns K, Peters GJ, Judson IR, Leach MO, Griffiths JR. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. Cancer Chemother Pharmacol 2005;55:117-128.
10. Kamm YJ, Peters GJ, Hull WE, Punt CJ, Heerschap A. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 2003;89:754-762.
11. Kamm YJ, Heerschap A, Wagener DJ. Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma. Eur J Cancer 2000;36:1180-1186.
12. Katzir I, Shani J, Wolf W, Chatterjee-Parti S, Berman E. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy. Cancer Invest 2000;18:20-27.
13. Lemaire LP, McSheehy PM, Griffiths JR. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo. Cancer Chemother Pharmacol 1998;42:201-209.
14. McSheehy PM, Robinson SP, Ojugo AS, Aboagye EO, Cannell MB, Leach MO, Judson IR, Griffiths JR. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res 1998;58:1185-1194.
15. McSheehy PM, Seymour MT, Ojugo AS, Rodrigues LM, Leach MO, Judson IR, Griffiths JR. A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. Eur J Cancer 1997;33:2418-2427.
16. Holland SK, Bergman AM, Zhao Y, Adams ER, Pizzorno G. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn Reson Med 1997;38:907-916.
17. Blackstock AW, Kwock L, Branch C, Zeman EM, Tepper JE. Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1996;36:641-648.
18. Kamm VJ, Rietjens IM, Vervoort J, Heerschap A, Rosenbusch G, Hofs HP, Wagener DJ. Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy. Cancer Res 1994;54:4321-4326.
19. Shungu DC, Bhujwalla ZM, Li SJ, Rose LM, Wehrle JP, Glickson JD. Determination of absolute phosphate metabolite concentrations in RIF-1 tumors in vivo by 31P-1H-2H NMR spectroscopy using water as an internal intensity reference. Magn Reson Med 1992;28:105-121.
20. McSheehy PM, Prior MJ, Griffiths JR. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer 1989;60:303-309.
21. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM. Tumor uptake and elimination of 2′,2′-difluoro- 2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001;7:3263-3268.
22. Kristjansen PE, Quistorff B, Spang-Thomsen M, Hansen HH. Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. Ann Oncol 1993;4:157-160.
23. Brix G, Bellemann ME, Haberkorn U, Gerlach L, Bachert P, Lorenz WJ. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Magn Reson Med 1995;34:302-307.
24. Brunstein F, Eggermont AMM, Aan de Wiel-Ambagtsheer G, Van Tiel ST, Rens J, Ten Hagen TLM. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007;14:795-801.
25. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases. Clin Cancer Res 2006;12:3115-3123.
26. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Gregoire V, Balligand JL, Feron O. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004;64:3209-3214.
27. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Gregoire V, Feron O, Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-750.
28. Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 2006;244:129-135.
29. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
30. Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, De Wever J, Verrax J, Wauthier V, Beghein N, Gregoire V, Buc Calderon P, Feron O, Gallez B. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006;12:1276-1283.
31. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689.
32. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study on Atrensentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107:530-535.
33. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. Br J Urol 2007;99:1047-1055.
34. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003;29:549-556
35. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143-148.
36. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000;47:785-791.
37. Gudbjartsson H, Patz S. The rician distribution of noisy MRI data. Magn Reson Med 1995;34:910-914.
38. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-163.